• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma.
【24h】

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma.

机译：I类组蛋白脱乙酰基酶1、2和3在经典霍奇金淋巴瘤中高表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: HDAC inhibitors (HDI) are anti-neoplastic drugs with preliminary successful clinical applications in Hodgkin's lymphoma (HL). Systematic investigations of HDAC expression in HL, based on histology and immunohistochemistry are yet rare. RESEARCH DESIGN/METHODS: We investigated the expression of HDAC1, 2 and 3 in 283 HL on tissue microarrays. Main outcome measures: Expression of HDAC isoforms was scored in Hodgkin and Reed-Sternberg cells (HRSC) and background infiltrate and compared with freedom of treatment failure (FTF) in 118 cases, for which all data was available. RESULTS: All analyzable HL expressed the HDAC isoforms 2 (n = 194) and 3 (n = 207) in over 50%, mostly 100%, of HRSC and almost all background lymphocytes. HDAC1 was expressed in 169 of 179 analyzable HL in a mean of 82% and in 172 out of 179 analyzable cases in a mean of 83% of infiltrating lymphocytes. HDAC1 of below 75% in HRSC correlated with worse FTF with 16 out of 32 events, compared with 16 out of 82 in cases with over 75% HDAC1-expressing HRSC. CONCLUSION: HDAC isoforms 1, 2 and 3 are highly expressed in HL. In addition, decreased HDAC1 expression is accompanied by worse outcome in HL.
机译：目的：HDAC抑制剂（HDI）是抗肿瘤药物，在霍奇金淋巴瘤（HL）中具有初步的临床成功应用。基于组织学和免疫组化的HDAC HDAC表达的系统研究仍然很少。研究设计/方法：我们研究了组织芯片上HDAC1、2和3在283 HL中的表达。主要结局指标：在Hodgkin和Reed-Sternberg细胞（HRSC）和背景浸润中对HDAC亚型的表达进行了评分，并与118例治疗失败自由度（FTF）进行了比较，所有数据均可获得。结果：所有可分析的HL在50％以上（大部分为100％）的HRSC和几乎所有背景淋巴细胞中均表达HDAC同种型2（n = 194）和3（n = 207）。 HDAC1在179个可分析的HL中的169个中平均表达82％，在179个可分析的病例中的172个中平均83％的浸润淋巴细胞表达。 HRSC中低于75％的HDAC1与较差的FTF相关（32个事件中有16个事件），而HDAC1表达超过75％的HRSC中82个事件中有16个事件。结论：HDAC同工型1、2和3在HL中高表达。此外，HDAC1表达降低伴随着HL患者预后不良。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号